Tuesday, April 28, 2026

CMS and the FDA have formally launched the RAPID Medicare Coverage pathway for FDA-designated breakthrough devices. This new program aims to accelerate national Medicare coverage decisions, potentially within six months of FDA market authorization, by aligning CMS and FDA reviews. The pathway is voluntary for device sponsors and begins immediately. For billing teams, this signals that coverage for novel, high-impact devices could arrive faster and with more predictable timelines. Monitor CMS transmittals for specific devices entering the program, as coverage determinations will be posted publicly.

UnitedHealthcare, Aetna, Cigna, and the Blue Cross Blue Shield Association report meeting 2025 goals to standardize electronic prior authorization for certain medical services and drugs. The initiative, part of an industry-wide commitment brokered with the AMA, focused on adopting HL7's Da Vinci standards for attachments and documentation requirements. While payers claim an 11% reduction in PA volume, practice-level impact varies. This reflects continued payer and regulatory pressure to streamline PA but does not yet mandate specific workflow changes for providers. The operational reality remains that PA rules and requirements are still payer-specific.

A CMS AI-driven prior authorization pilot in Washington state is delaying care for seniors, according to a report cited by Senator Maria Cantwell. The pilot, which uses algorithms to review PA requests for certain durable medical equipment and procedures, has generated denials and lengthy review times that exceed Medicare's mandated 14-day decision window. For practices in Washington, this means increased administrative burden to track and appeal delayed PA decisions for Medicare patients. Immediately audit any outstanding PA requests for Medicare patients in your Washington state panels; prepare for appeals and document all communication timelines.

CMS has issued the final Call Letter and rate announcement for Medicare Advantage and Part D plans for calendar year 2027. The policies set reimbursement rates, benefit design parameters, and Star Ratings measures that will govern the private plans used by over half of Medicare beneficiaries. Practices should expect these finalized rules to shape the prior authorization, network, and formulary landscape their Medicare patients face next year. Monitor plan-specific bid submissions and benefit announcements from UHC, Humana, and other MA carriers through the fall.

CMS and the FDA have launched the RAPID Coverage Pathway, a new joint initiative to accelerate Medicare coverage for FDA-designated breakthrough medical devices. The program aims to synchronize FDA review and CMS national coverage determination processes, reducing the lag time between market approval and Medicare reimbursement. This policy shift is intended to speed patient access to novel technologies in cardiology, orthopedics, and oncology. While the direct impact on billing workflows is limited for now, the move signals CMS's continued focus on value-based technology adoption and may influence future coverage decisions for high-cost, innovative procedures.